Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload ...
Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE ®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart ...
An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic ...
Antibody-Drug Conjugates (ADCs) are a fast-growing modality in both cancerous and non-cancerous indications. To date 15 ADCs have been approved by the regulatory agencies as therapies for various ...
Akari’s lead program, AKTX-101, a TROP2-targeting ADC powered by its proprietary PH1 payload, is currently in IND-enabling ...
TOKYO, JAPAN, February 10, 2026 /EINPresswire.com/ — Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter “Chugai”) and Araris Biotech AG (hereafter ...
The trial assesses Precem-TcT efficacy and safety alone or with bevacizumab in mCRC patients after previous therapies.
Antibody-drug conjugate (ADC) is a promising class of cancer treatments with accelerating U.S. Food and Drug Administration (FDA) approval and rapidly growing market size as discussed in previous ...
Pharmaceutical Technology on MSN
Gilead Sciences completes Tubulis acquisition for $5bn
Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results